Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (AMRN) delivers innovative cardiovascular therapeutics through advanced lipid science, anchored by its FDA-approved therapy VASCEPA®. This page provides direct access to official company announcements, clinical research updates, and regulatory developments.
Investors and healthcare professionals will find curated press releases covering drug approvals, global expansion efforts, and peer-reviewed study results. Key updates include milestones from the landmark REDUCE-IT trial, intellectual property developments, and strategic partnerships enhancing patient access to cardiovascular care solutions.
All content is sourced from Amarin's corporate communications, ensuring accuracy and timeliness. Bookmark this page for streamlined tracking of AMRN's progress in addressing persistent cardiovascular risk through scientifically validated therapies.
Rhea-AI Summary
Amarin plc (NASDAQ:AMRN) has received a Decision to Grant from the European Patent Office (EPO) for a new patent extending VAZKEPA exclusivity in Europe until 2039. This extends the commercial runway for VAZKEPA by eight additional years, reinforcing the Company's IP rights and strengthening its position in the European market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
-
Rhea-AI Summary
Amarin plc (AMRN) announced additional patient subgroup analyses from the REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) to be presented at the American College of Cardiology's Annual Scientific Session. The data supports VASCEPA/VAZKEPA's efficacy in reducing cardiovascular events across different patient subgroups, regardless of baseline Lipoprotein(a) or LDL-C levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
News
Rhea-AI Summary
Amarin Corporation plc (AMRN) reports total revenues of $75 million in Q4 and $306 million for full-year 2023. They reaffirm a year-end cash position of $321 million and a positive cash flow of $10 million for 2023. The company plans to execute a share repurchase program of up to $50 million by Q2 2024. Despite a decrease in net product revenue, Amarin remains focused on building momentum in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.94%
Tags
Rhea-AI Summary
Amarin Corporation plc (AMRN) will host a conference call to discuss its fourth quarter and year-end 2023 results on February 29th, 2024. The call will include a Q&A session and highlights from 2023. Shareholders can submit questions through Say Technologies for the earnings call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced a letter to shareholders highlighting significant actions taken to strengthen the company, including leadership restructuring, operational improvements, and financial discipline. The company's focus on extending market leadership in the U.S., accelerating revenues in Europe, and advancing market access in the Rest of World (RoW) positions it for shareholder value in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (AMRN) reported unaudited total revenues of $72-74 million in Q4 2023, ending the year with a cash position of $321 million and delivering full-year positive cash flow of ~$10 million. The company's 2024 priorities include accelerating revenue in key European launch markets, retaining IPE market leadership in the US, and maximizing patient uptake in Rest of World (RoW) through partnerships. Amarin also announced a plan to initiate a share repurchase program of up to $50 million. The company will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.99%
Tags
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) is set to participate in the 42nd Annual JP Morgan Healthcare Conference, with President and CEO Patrick Holt scheduled to present on January 10, 2024. The webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
News
Rhea-AI Summary
Sarissa Capital Management LP (Sarissa) issued a statement regarding Amarin Corporation plc (NASDAQ: AMRN), expressing belief in the significant undervaluation of Amarin's stock. Sarissa remains a long-term shareholder and has been purchasing shares at depressed prices, never having sold any shares. The company has made progress in reorganizing its leadership team, streamlining its U.S. business, reworking Europe's commercial infrastructure, achieving national reimbursement approvals and launches of Vazkepa in Europe and securing international partnership deals. Sarissa acknowledges that turning around companies takes time and is pleased with Amarin's progress, expecting the value to be reflected in the stock price over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced findings from new REDUCE-IT analyses, revealing that VASCEPA/VAZKEPA significantly reduced the risk of first and total cardiovascular events in a subgroup of statin-treated patients with Metabolic Syndrome but without diabetes. The results were presented at the American Heart Association Scientific Sessions 2023 and simultaneously published in the European Heart Journal Open. The findings support IPE as an important therapeutic option for patients with Metabolic Syndrome at high cardiovascular risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Amarin Corporation reported total net revenues of $66 million in the third quarter of 2023. They achieved positive cash flow of $8 million, marking the fifth consecutive quarter of cash positive operations. The company's quarter-ending cash position was $321 million. Amarin continues to deliver significant U.S. profit through the extended lifecycle and market leadership of their branded product VASCEPA®. They have also made progress with the early launch of VASCEPA® in European countries driven by new leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Amarin
Nasdaq:AMRN
AMRN Rankings
AMRN Stock Data
188.66M
20.55M
1.63%
18.07%
4.08%
Drug Manufacturers - General
Pharmaceutical Preparations
Ireland
DUBLIN 2